IL2 and neoplasm: The decreased proportion of PD-1+ Pmel-1 in the TBI/IL-2-treated tumor was also consistent with the former data (Figure 3F and Figure 5B), indicating that these groups have an immunological status equivalent to that of the experimental setting shown in Figure 2 and Figure 3.